Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
PhIP-induced skin tumors were subjected to mutation screening, which identified genetic changes in Hras (7/40, 17.5%) and Tp53 (2/40, 5%), but not in Ctnnb1, a commonly mutated gene in PhIP-induced colon tumors.
|
28218467 |
2017 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We also observed the inactivation of β-catenin/TCF signaling after CBB1003 treatment, consistent with the positive correlations among LSD1, LGR5, β-catenin and c-Myc expression in human colon tumor and adenoma tissues.
|
25060070 |
2015 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The mechanism by which sulindac sulfide and the cGMP/PKG pathway inhibits colon tumor cell growth involves the transcriptional suppression of β-catenin to inhibit Wnt/β-catenin T-cell factor transcriptional activity, leading to downregulation of cyclin D1 and survivin.
|
23804703 |
2013 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In mice, SMAC deficiency significantly increased the incidence and size of colon tumors induced by azoxymethane (AOM)/dextran sulfate sodium salt (DSS), and highly enriched β-catenin hot spot mutations.
|
22751125 |
2013 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
SPDEF inhibited the expression of β-catenin-target genes in mouse colon tumors, and interacted with β-catenin to block its transcriptional activity in CRC cell lines, resulting in lower levels of cyclin D1 and c-MYC.
|
23376423 |
2013 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.
|
22556201 |
2012 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.
|
22323126 |
2012 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Activation of the β-catenin/T-cell factor (TCF) complex occurs in most colon tumors, and its actions correlate with the neoplastic phenotype of intestinal epithelial cells.
|
22771508 |
2012 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In a converse experiment, the forced expression of LPP3 in human colon tumor (SW480) cells potentiated tumor growth via increased β-catenin stability and CYCLIN-D1 synthesis.
|
21569306 |
2011 |
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Analysis of β-catenin alterations in colon tumors: a novel exon 3 mutation.
|
20717765 |
2011 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Rapid induction of colon carcinogenesis in CYP1A-humanized mice by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate.
|
21081470 |
2011 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Murine deletion of Cck2r abrogated progastrin-dependent increases in colonic proliferation, mucosal thickness, and beta-catenin and CD44 expression in the colon tumor.
|
19652364 |
2009 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of Apc/beta-catenin/Tcf pathway may play a role in Paneth cell differentiation in human colonic neoplasms.
|
19269007 |
2009 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
In the colon tumors, beta-catenin mutations were detected at a higher frequency after caffeine posttreatment, and there was a shift toward more tumors harboring substitutions of Gly34 with correspondingly high protein and messenger RNA expression seen for both beta-catenin and c-Myc. c-Myc expression exhibited concordance with tumor promotion, and there was a concomitant increase in cell proliferation versus apoptosis in colonic crypts.
|
18283038 |
2008 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells.
|
18161931 |
2007 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
beta-Catenin signaling in biological control and cancer.
|
17854061 |
2007 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These findings suggest an indirect pathway for Bcl-2 over-expression in PhIP-induced colon tumors involving beta-catenin, c-Myc and E2F1.
|
17404573 |
2007 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes.
|
17128412 |
2007 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
These findings suggest an indirect pathway for Bcl-2 over-expression in PhIP-induced colon tumors involving beta-catenin, c-Myc and E2F1.
|
17404573 |
2007 |
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Reciprocal targeting of Hath1 and beta-catenin by Wnt glycogen synthase kinase 3beta in human colon cancer.
|
17241872 |
2007 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.
|
17638895 |
2007 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Nitric oxide-induced down-regulation of beta-catenin in colon cancer cells by a proteasome-independent specific pathway.
|
17030184 |
2006 |
Colonic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The finding of LOH in ACF with normal expressions of adenomatous polyposis coli (APC) and beta-catenin proteins suggests that LOH can occur very early in colon neoplasia and perhaps even before APC mutations.
|
16474178 |
2006 |
Colonic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Overexpressed LEF-1 proteins display different nuclear localization patterns of beta-catenin in normal versus tumor cells.
|
16378739 |
2006 |
Colonic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition, we found that the beta-catenin protein was accumulated in cytoplasm and nuclei of MDF and the frequent beta-catenin gene mutations in the colon tumors.
|
16761624 |
2006 |